Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Methylnaltrexone Extension in Advanced Pancreatic Cancer
NCT04151719Phase 3Withdrawn
- Sponsor
- Valeant Pharmaceuticals
- Start
- Feb 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of methylnaltrexone in Pancreatic ductal adenocarcinoma (PDAC), sponsored by Valeant Pharmaceuticals. Primary endpoint: Overall Survival up to 4 years. Planned start Feb 2020; status: withdrawn.
02
Drugs
methylnaltrexone
03
Conditions
Pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04151719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151719.